NuCana plc

NuCana plc

NuCana plc was incorporated in 2015 as a spinout from Griffith University and pharmaceutical consultancy, with Hugh Griffiths serving as chairman and CEO through 2023. The firm emerged from the ProTide drug-delivery platform, originally developed by Dr. David H. Evans and colleagues. Primary financing came from equity raises on the London Stock Exchange's AIM market and later the NASDAQ, where NuCana listed in 2017. The company's pipeline centers on two ProTide-modified nucleoside analogs: NUC-3373 (a reformulation of the colorectal cancer drug FUDR) and NUC-1031 (a reformulation of gemcitabine). Both drugs incorporate a phosphoramidate prodrug strategy intended to bypass cellular resistance mechanisms. NuCana has evaluated these candidates in Phase 1, 2, and 3 trials across multiple indications including advanced colorectal, pancreatic, and lung cancers. Clinical data from several studies have been reported at ASCO and other oncology conferences (per NuCana press releases, 2020–2025). As of the most recent filings, NuCana maintained cash reserves of roughly £18 million, sufficient to fund operations into mid-2025 (per the 2023 annual report). The firm employs approximately 20 full-time staff, with preclinical chemistry outsourced to contract research organizations. Notable shareholders include institutional investors like Orbimed Advisors and certain UK-based fund managers. NuCana's structural differentiator is its exclusive focus on a single technology platform — the ProTide delivery system originally developed for antiviral drugs (notably, remdesivir) and now applied to oncology. No other publicly held biotech has dedicated its entire pipeline to ProTide-modified nucleosides. This narrow mandate creates both risk and potential upside: if NUC-3373 or NUC-1031 succeed, they represent platform-validation rather than single-asset events.